Anixa Secures Korean Patent for Breast Cancer Vaccine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ANIX?
Source: PRnewswire
- Patent Approval: Anixa has received a Notice of Allowance from the Korean Ministry of Intellectual Property for its breast cancer vaccine technology, marking a significant advancement in the company's global intellectual property strategy and reinforcing its leadership in cancer immunotherapy.
- Clinical Trial Success: In a Phase 1 clinical trial conducted at Cleveland Clinic, the vaccine generated immune responses in 74% of participants, demonstrating good safety and tolerability, thus laying the groundwork for continued clinical development.
- Growing Market Demand: While breast cancer survival rates are high in South Korea, the incidence is rapidly increasing, particularly among younger women, and Anixa's vaccine aims to address the current gap in preventive vaccines, meeting the rising demand.
- Global Strategic Expansion: By strengthening its international patent portfolio, Anixa is laying the groundwork for future international development and commercialization strategies, potentially partnering with larger pharmaceutical companies to advance its vaccine technology globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANIX
Wall Street analysts forecast ANIX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.980
Low
10.00
Averages
10.00
High
10.00
Current: 2.980
Low
10.00
Averages
10.00
High
10.00
About ANIX
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anixa Secures Korean Patent for Breast Cancer Vaccine
- Patent Approval: Anixa has received a Notice of Allowance from the Korean Ministry of Intellectual Property for its breast cancer vaccine technology, marking a significant advancement in the company's global intellectual property strategy and reinforcing its leadership in cancer immunotherapy.
- Clinical Trial Success: In a Phase 1 clinical trial conducted at Cleveland Clinic, the vaccine generated immune responses in 74% of participants, demonstrating good safety and tolerability, thus laying the groundwork for continued clinical development.
- Growing Market Demand: While breast cancer survival rates are high in South Korea, the incidence is rapidly increasing, particularly among younger women, and Anixa's vaccine aims to address the current gap in preventive vaccines, meeting the rising demand.
- Global Strategic Expansion: By strengthening its international patent portfolio, Anixa is laying the groundwork for future international development and commercialization strategies, potentially partnering with larger pharmaceutical companies to advance its vaccine technology globally.
See More
Anixa Biosciences Secures Patent Allowance in South Korea
- Patent Allowance Granted: Anixa Biosciences announced that the Korean Ministry of Intellectual Property has issued a Notice of Allowance for its breast cancer vaccine platform, exclusively licensed from Cleveland Clinic, marking a significant advancement in the company's global intellectual property expansion.
- Patent Content Protection: The patent, titled 'Vaccine Adjuvants and Formulations,' provides composition of matter protection in South Korea, further complementing Anixa's existing patents in the U.S. and other jurisdictions, thereby enhancing its competitive position in the market.
- Commercialization Potential: This patent approval not only supports Anixa's global intellectual property expansion but also lays the groundwork for potential commercialization efforts outside the United States, which could lead to new revenue streams for the company.
- Market Reaction: Anixa's stock fell 1.75% in premarket trading to $2.8, reflecting market caution regarding its vaccine development progress, despite the patent allowance presenting new growth opportunities for the company.
See More
Anixa Biosciences to Host 2026 Annual Stockholders Meeting
- Annual Meeting Announcement: Anixa Biosciences will hold its 2026 Annual Stockholders Meeting on March 10, 2026, in a virtual format, expected to attract broad participation, including non-stockholders, aimed at enhancing company transparency and fostering investor relations.
- Clinical Progress Update: During the meeting, Anixa's Chairman and CEO Dr. Amit Kumar will present recent clinical milestones in the oncology pipeline, particularly focusing on the development of CAR-T therapy for ovarian cancer and breast cancer vaccines, showcasing the company's innovative potential in cancer treatment.
- Collaborative R&D Model: Anixa's partnerships with Moffitt Cancer Center and Cleveland Clinic drive the development of its unique CAR-T technology and cancer vaccines, indicating the company's strategy of continuously exploring emerging technologies through collaborations with leading research institutions for commercialization.
- Forward-Looking Statements: Anixa emphasizes its forward-looking statements, noting that future results may be influenced by various risks and uncertainties, cautioning investors to exercise care when evaluating the information presented to ensure a clear understanding of the company's future developments.
See More
Anixa Biosciences to Host 2026 Annual Stockholders Meeting
- Clinical Milestone Update: Anixa Biosciences will host its Annual Stockholders Meeting on March 10, 2026, where it will present survival observations and regulatory approval for dose escalation in its ovarian cancer CAR-T trial, indicating ongoing progress in cancer treatment that may attract more investor interest.
- Vaccine Program Progress: The meeting will also reveal final Phase 1 data from Anixa's breast cancer vaccine program, which met primary endpoints and demonstrated favorable tolerability and immune responses in most participants, suggesting potential market demand for cancer prevention solutions.
- Technological Collaboration Advantage: Anixa's lira-cel immunotherapy, developed in collaboration with Moffitt Cancer Center, utilizes a novel CAR-T technology that directly targets tumor cells via the natural ligand of the FSHR receptor, showcasing its uniqueness in cancer immunotherapy and potentially providing a competitive edge.
- Innovative Business Model: Anixa's strategy of partnering with renowned research institutions allows for continuous exploration of emerging technologies aimed at developing vaccines for various intractable cancers, reflecting its strategic foresight in the cancer treatment sector and potentially leading to long-term growth opportunities.
See More
Anixa Biosciences Updates on Ovarian Cancer CAR-T Trial Outcomes
- Improved Patient Survival: In Anixa's ovarian cancer CAR-T clinical trial, of the 12 treated patients, 7 have exceeded the expected median survival of 3 to 4 months, indicating the potential effectiveness and hope of the treatment.
- Long-Term Survival Cases: One patient survived 28 months post-treatment, while three others have survived over a year (17, 15, and 14 months respectively), suggesting that this therapy may provide new survival opportunities for patients with recurrent ovarian cancer.
- Good Safety Profile: No dose-limiting toxicities (DLTs) have been observed to date, allowing Anixa's partner, Moffitt Cancer Center, to obtain IRB approval for significant dose escalation, further validating the safety and efficacy of the therapy.
- Dose Escalation Plan: Under the amended protocol, the CAR-T cell dosage will increase from 1×10⁵ to 1×10⁷ cells per kilogram to as high as 1×10⁹ cells, representing a two-order-of-magnitude increase that may enhance treatment efficacy, especially following lymphodepletion treatment.
See More
Anixa Biosciences' CAR-T Therapy Receives Naming Approval
- Naming Approval: Anixa Biosciences' FSHR-targeted CAR-T therapy, “liraltagene autoleucel,” has received approval from the US Adopted Names Council, marking a significant step in the global commercialization process by ensuring a universally recognized and conflict-free drug name.
- Clinical Trial Progress: The therapy is currently undergoing a Phase 1 clinical trial in partnership with Moffitt Cancer Center, aimed at evaluating its safety and clinical activity in patients with recurrent ovarian cancer, which is expected to provide crucial data for future treatment options.
- Technological Innovation: Liraltagene autoleucel utilizes a novel CER-T technology that specifically targets the FSHR receptor, uniquely expressed in normal ovarian cells and tumor vasculature, potentially offering new hope for ovarian cancer treatment and enhancing Anixa's competitive edge in the biotechnology sector.
- Partnership Strength: Anixa's collaboration with the world-renowned Moffitt Cancer Center solidifies its position in cancer immunotherapy and expands its cancer treatment portfolio through partnerships with Cleveland Clinic for vaccine development, showcasing its unique business model and research capabilities.
See More
Anixa Secures Korean Patent for Breast Cancer Vaccine
- Patent Approval: Anixa has received a Notice of Allowance from the Korean Ministry of Intellectual Property for its breast cancer vaccine technology, marking a significant advancement in the company's global intellectual property strategy and reinforcing its leadership in cancer immunotherapy.
- Clinical Trial Success: In a Phase 1 clinical trial conducted at Cleveland Clinic, the vaccine generated immune responses in 74% of participants, demonstrating good safety and tolerability, thus laying the groundwork for continued clinical development.
- Growing Market Demand: While breast cancer survival rates are high in South Korea, the incidence is rapidly increasing, particularly among younger women, and Anixa's vaccine aims to address the current gap in preventive vaccines, meeting the rising demand.
- Global Strategic Expansion: By strengthening its international patent portfolio, Anixa is laying the groundwork for future international development and commercialization strategies, potentially partnering with larger pharmaceutical companies to advance its vaccine technology globally.
See More
Anixa Biosciences Secures Patent Allowance in South Korea
- Patent Allowance Granted: Anixa Biosciences announced that the Korean Ministry of Intellectual Property has issued a Notice of Allowance for its breast cancer vaccine platform, exclusively licensed from Cleveland Clinic, marking a significant advancement in the company's global intellectual property expansion.
- Patent Content Protection: The patent, titled 'Vaccine Adjuvants and Formulations,' provides composition of matter protection in South Korea, further complementing Anixa's existing patents in the U.S. and other jurisdictions, thereby enhancing its competitive position in the market.
- Commercialization Potential: This patent approval not only supports Anixa's global intellectual property expansion but also lays the groundwork for potential commercialization efforts outside the United States, which could lead to new revenue streams for the company.
- Market Reaction: Anixa's stock fell 1.75% in premarket trading to $2.8, reflecting market caution regarding its vaccine development progress, despite the patent allowance presenting new growth opportunities for the company.
See More
Anixa Biosciences to Host 2026 Annual Stockholders Meeting
- Annual Meeting Announcement: Anixa Biosciences will hold its 2026 Annual Stockholders Meeting on March 10, 2026, in a virtual format, expected to attract broad participation, including non-stockholders, aimed at enhancing company transparency and fostering investor relations.
- Clinical Progress Update: During the meeting, Anixa's Chairman and CEO Dr. Amit Kumar will present recent clinical milestones in the oncology pipeline, particularly focusing on the development of CAR-T therapy for ovarian cancer and breast cancer vaccines, showcasing the company's innovative potential in cancer treatment.
- Collaborative R&D Model: Anixa's partnerships with Moffitt Cancer Center and Cleveland Clinic drive the development of its unique CAR-T technology and cancer vaccines, indicating the company's strategy of continuously exploring emerging technologies through collaborations with leading research institutions for commercialization.
- Forward-Looking Statements: Anixa emphasizes its forward-looking statements, noting that future results may be influenced by various risks and uncertainties, cautioning investors to exercise care when evaluating the information presented to ensure a clear understanding of the company's future developments.
See More
Anixa Biosciences to Host 2026 Annual Stockholders Meeting
- Clinical Milestone Update: Anixa Biosciences will host its Annual Stockholders Meeting on March 10, 2026, where it will present survival observations and regulatory approval for dose escalation in its ovarian cancer CAR-T trial, indicating ongoing progress in cancer treatment that may attract more investor interest.
- Vaccine Program Progress: The meeting will also reveal final Phase 1 data from Anixa's breast cancer vaccine program, which met primary endpoints and demonstrated favorable tolerability and immune responses in most participants, suggesting potential market demand for cancer prevention solutions.
- Technological Collaboration Advantage: Anixa's lira-cel immunotherapy, developed in collaboration with Moffitt Cancer Center, utilizes a novel CAR-T technology that directly targets tumor cells via the natural ligand of the FSHR receptor, showcasing its uniqueness in cancer immunotherapy and potentially providing a competitive edge.
- Innovative Business Model: Anixa's strategy of partnering with renowned research institutions allows for continuous exploration of emerging technologies aimed at developing vaccines for various intractable cancers, reflecting its strategic foresight in the cancer treatment sector and potentially leading to long-term growth opportunities.
See More
Anixa Biosciences Updates on Ovarian Cancer CAR-T Trial Outcomes
- Improved Patient Survival: In Anixa's ovarian cancer CAR-T clinical trial, of the 12 treated patients, 7 have exceeded the expected median survival of 3 to 4 months, indicating the potential effectiveness and hope of the treatment.
- Long-Term Survival Cases: One patient survived 28 months post-treatment, while three others have survived over a year (17, 15, and 14 months respectively), suggesting that this therapy may provide new survival opportunities for patients with recurrent ovarian cancer.
- Good Safety Profile: No dose-limiting toxicities (DLTs) have been observed to date, allowing Anixa's partner, Moffitt Cancer Center, to obtain IRB approval for significant dose escalation, further validating the safety and efficacy of the therapy.
- Dose Escalation Plan: Under the amended protocol, the CAR-T cell dosage will increase from 1×10⁵ to 1×10⁷ cells per kilogram to as high as 1×10⁹ cells, representing a two-order-of-magnitude increase that may enhance treatment efficacy, especially following lymphodepletion treatment.
See More
Anixa Biosciences' CAR-T Therapy Receives Naming Approval
- Naming Approval: Anixa Biosciences' FSHR-targeted CAR-T therapy, “liraltagene autoleucel,” has received approval from the US Adopted Names Council, marking a significant step in the global commercialization process by ensuring a universally recognized and conflict-free drug name.
- Clinical Trial Progress: The therapy is currently undergoing a Phase 1 clinical trial in partnership with Moffitt Cancer Center, aimed at evaluating its safety and clinical activity in patients with recurrent ovarian cancer, which is expected to provide crucial data for future treatment options.
- Technological Innovation: Liraltagene autoleucel utilizes a novel CER-T technology that specifically targets the FSHR receptor, uniquely expressed in normal ovarian cells and tumor vasculature, potentially offering new hope for ovarian cancer treatment and enhancing Anixa's competitive edge in the biotechnology sector.
- Partnership Strength: Anixa's collaboration with the world-renowned Moffitt Cancer Center solidifies its position in cancer immunotherapy and expands its cancer treatment portfolio through partnerships with Cleveland Clinic for vaccine development, showcasing its unique business model and research capabilities.
See More
